trial

A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia

NCTId NCT02220712
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 17 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2015-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
17 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2014-07
Primary completion
2015-04
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Investigators

1
Jun-ichi Hashimoto, PhDStudy Director

Sites

0 total

Facts & assertions

4 sourced
Enrollment
17
Phase
PHASE1
Primary Completion Date
2015-04
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jun-ichi Hashimoto, PhD
person